Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 8,888 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 73,149 shares.
However, the script later moved the day high at 5.3600, up 31.38%. The company’s stock has a 5-day price change of -37.85% and -74.68% over the past three months. PBLA shares are trading -76.67% year to date (YTD), with the 12-month market performance down to -99.74% lower. It has a 12-month low price of $3.07 and touched a high of $1170.00 over the same period. PBLA has an average intraday trading volume of 297.21K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -63.26%, -65.30%, and -94.19% respectively.
Institutional ownership of Panbela Therapeutics Inc. (NASDAQ: PBLA) shares accounts for 4.74% of the company’s. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $2.05M and a beta (3y monthly) value of 0.79. The earnings-per-share (ttm) stands at -$4016.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 32.73% over the week and 18.55% over the month.
Analysts forecast that Panbela Therapeutics Inc. (PBLA) will achieve an EPS of -$24.6 for the current quarter, -$15.8 for the next quarter and -$62.7 for 2024. The lowest estimate earnings-per-share for the quarter is -$28.4 while analysts give the company a high EPS estimate of -$20.8. Comparatively, EPS for the current quarter was -$3,408 a year ago. Earnings per share for the fiscal year are expected to increase by 99.50%, and 69.50% over the next financial year.
